Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
91. |
ECCT/23/05/04 | PRIORITY Trial Prevention of Iron Deficiency Anemia Post-delivery |
Principal Investigator(s) 1. FABIAN OMODING ESAMAI 2. PAUL OBANDA NYONGESA Site(s) in Kenya BUSIA COUNTY REFERRAL HOSPITAL |
View |
92. |
ECCT/23/05/03 | BrainCapture EEG Validation Usability and efficacy of an affordable, smartphone-connected EEG device to bridge the global gap in epilepsy diagnosis |
Principal Investigator(s) 1. Diraj Sokhi Sokhi Site(s) in Kenya Aga Khan University Hospital Nairobi |
View |
93. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
94. |
ECCT/23/05/01 | A5356 A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTRE |
View |
95. |
ECCT/23/04/05 | BiMVaC01 A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults. |
Principal Investigator(s) 1. NDUNGU FRANCIS 2. Said Jongo Site(s) in Kenya KEMRI-CGMRC Kilifi |
View |